New Immunotherapy Drugs Combined With Chemotherapy for Advanced Esophageal Cancer

Plain-English translation of NCT07290010 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination of two immunotherapy drugs called iparomlimab and tuvonralimab, given together with two chemotherapy drugs (paclitaxel and cisplatin), to treat advanced or recurrent esophageal squamous cell carcinoma. The study will enroll about 25 patients and track how well this medication combination works and how safe it is. Researchers want to see if the treatment can shrink tumors and help patients live longer.

Esophageal cancer that has spread or come back after treatment is very difficult to treat, and patients need better options. This medication combination is designed to boost the body's immune system to fight the cancer cells while chemotherapy also works to destroy them.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with esophageal squamous cell carcinoma that cannot be surgically removed or has come back after treatment
if you received chemotherapy or radiation before, at least 6 months have passed since your last treatment before the cancer returned
you are in good enough health to handle the treatment (your doctor will assess this)
you have at least one tumor that can be measured on imaging scans
your blood, heart, lung, liver, and kidney function are normal or near-normal

You likely don't qualify if…

you have received chemotherapy or other systemic treatment for advanced esophageal cancer before
you have had another cancer (other than certain skin cancers or early-stage cervical or breast cancer) diagnosed in the past 5 years
you have a serious infection, active tuberculosis, or severe lung disease
you have HIV, active hepatitis B or C, or a weakened immune system from other causes
you are currently participating in another drug or treatment study at the same time

What participation looks like

You will receive 6 cycles of the medication combination given by IV infusion every 3 weeks (about 18 weeks total). Then, if the cancer responds well, you will continue with maintenance treatment using the immunotherapy drugs, with or without additional chemotherapy, until your cancer progresses or side effects become too severe. The total treatment time can be up to 24 months, and you will have regular clinic visits, blood tests, and imaging scans to monitor how you are responding.

AI-generated summary from trial data · Jul 18, 2026 · Not medical advice

New Immunotherapy Drugs Combined With Chemotherapy for Advanced Esophageal Cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations